MetaCap

Aura Biosciences (AURA) vs Monte Rosa Therapeutics (GLUE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aura Biosciences (AURA) has outperformed Monte Rosa Therapeutics (GLUE) over the past year, gaining 26.3% versus a loss of 39.2%. Over five years, GLUE leads with a -58.0% price change compared with -69.6% for AURA. Monte Rosa Therapeutics is the larger company by market cap ($738.3 million vs $715.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+26.29%GLUE-39.24%
+84%+19%-45%
Nov 21, 20251 yearNov 20, 2026
AURA-69.47%GLUE-55.85%
+31%-30%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus GLUE key metrics
MetricAURAGLUE
Share price$6.87$8.64
Market cap$714.99M$738.29M
1-day change-1.58%-3.03%
YTD return+26.06%-44.90%
1-year return+26.29%-39.24%
5-year return-69.63%-57.96%
EPS (TTM)$-1.59$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$123.67M
Revenue growth (YoY)—+63.54%
Net income (latest FY)$-106.19M$-38.60M
Operating margin—-43.83%
Net margin—-31.21%
52-week high$9.54$25.77
52-week low$4.73$8.48
Distance from 52-week high-27.95%-66.47%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+141.63%+193.75%
Average volume847.22K1.37M
Shares outstanding104.07M85.45M
Employees113185
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AURA has outperformed GLUE by 65.5 percentage points over the past year.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Monte Rosa Therapeutics

GLUE stock →

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 185 employees

AURA vs GLUE FAQ

Which is bigger, Aura Biosciences or Monte Rosa Therapeutics?

Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $738.29M compared with $714.99M for Aura Biosciences (AURA).

Which stock has performed better over the past year, AURA or GLUE?

AURA returned +26.29% over the past 12 months, compared with -39.24% for GLUE (price return, excluding dividends). Past performance does not predict future results.

Are Aura Biosciences and Monte Rosa Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons